Ovarian Cancer Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

November 10 15:05 2022
Ovarian Cancer Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Ovarian Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from Ovarian Cancer Pipeline Insight Report

  • DelveInsight’s Ovarian Cancer Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Ovarian Cancer.
  • The leading Ovarian Cancer Companies such as Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others are developing potential drug candidates to improve the Ovarian Cancer treatment scenario.
  • Promising Ovarian Cancer Therapies such as Atezolizumab, Tisotumab Vedotin, Pembrolizumab, and others

 

Get an overview of the pipeline landscape @ Ovarian Cancer Clinical Trials Analysis

 

 

Ovarian Cancer Overview

Ovarian Cancer is a type of cancer that begins in a woman’s ovaries – the small organs in the female reproductive system that create eggs. This kind of cancer can be difficult to detect because it often doesn’t cause any symptoms until later stages. Once found, Ovarian Cancer can be treated with chemotherapy and surgery to remove any tumors. As with most cancers, Ovarian Cancer becomes more common as a person gets older. The risk of Ovarian Cancer increases steeply from around 45 years and is greatest in those aged between 75 and 79 years. Between 5 and 15 out of 100 Ovarian Cancers (5 to 15%) are caused by an inherited faulty gene. Inherited genes that increase the risk of Ovarian Cancer include faulty versions of BRCA1 and BRCA2. Faults in these genes also increase the risk of breast cancer.

 

Recent Breakthroughs of Ovarian Cancer Treatment Landscape

  • In May 2021, On Target Laboratories, Inc. declared results of the 006 Study, a Phase 3, randomized, multi-center, prospective, open-label study to study the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor-positive ovarian cancer.
  • In April 2021, Shenzhen Chipscreen Biosciences announced that it had received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to move ahead with a Phase 1b/2 clinical trial of Chiauranib/CS2164, a potential treatment for multiple oncological indications, including Small Cell Lung Cancer (SCLC), Ovarian Cancer, Liver Cancer, and Breast Cancer, etc. Chiauranib is the third novel drug candidate discovered and developed by Chipscreen to be marketed, submitted to NDA, or in the late-stage phases of clinical studies.
  • Stenoparib (2X-121) is a unique, small molecule dual-targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase II testing for ovarian cancer with patients selected by the Stenoparib DRP.
  • In June 2021, Apexigen, Inc., a clinical-stage biopharmaceutical company, focused on discovering and developing a new generation of antibody therapeutics for oncology. The Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU) declared an agreement to start a collaborative Phase 2 clinical study assessing sotigalimab, Apexigen’s monoclonal antibody targeting CD40, in combination therapy for patients with recurrent BRCA wild type ovarian cancer. Sotigalimab, Apexigen’s lead immuno-oncology therapeutic candidate, is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.
  • VBL Therapeutics’ lead oncology product candidate, VB-111 (ofranergene obadenovec), is a targeted anti-cancer gene-based biologic agent positioned to treat a wide range of solid tumors potentially. VB-111 has been observed to be well-tolerated in >300 cancer patients in an “all-comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies for Ovarian Cancer, recurrent Glioblastoma (rGBM), and Thyroid Cancer.  VB-111 is currently being studied in the OVAL Phase 3 study for platinum-resistant Ovarian Cancer.

 

For further information, refer to the detailed report @ Ovarian Cancer Pipeline Therapeutics

 

 

Ovarian Cancer Emerging Drugs

  • Atezolizumab: Genentech
  • Tisotumab Vedotin: Genmab
  • Pembrolizumab: Merck

 

DelveInsight’s Ovarian Cancer Pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Find out more about Ovarian Cancer Medication @ Ovarian Cancer Treatment

 

Scope of the Ovarian Cancer Pipeline Report

  • Coverage- Global
  • Ovarian Cancer Companies- Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others
  • Ovarian Cancer Therapies- Atezolizumab, Tisotumab Vedotin, Pembrolizumab, and others

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Ovarian Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Ovarian Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Ovarian Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Atezolizumab: Genentech
  11. Mid-Stage Products (Phase II)
  12. Tisotumab Vedotin: Genmab
  13. Inactive Products
  14. Ovarian Cancer Key Companies
  15. Ovarian Cancer Key Products
  16. Ovarian Cancer- Unmet Needs
  17. Ovarian Cancer- Market Drivers and Barriers
  18. Ovarian Cancer- Future Perspectives and Conclusion
  19. Ovarian Cancer Analyst Views
  20. Ovarian Cancer Key Companies
  21. Appendix

 

Dive deep into rich insights for drugs for Ovarian Cancer treatment, visit @ New Drug for Ovarian Cancer Treatment

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/